Biologic Product Exclusivity Decisions Will Involve Sponsor Dialogue, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
While FDA has laid out the types of information it wants sponsors to provide, agency acknowledges it cannot easily write guidance stating the extent of structural changes to a molecule that would justify a new period of exclusivity.